Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: IL-31

Search for Biomarkers

Analyte:

IL-31

Platform:

Matrix:

Human K2 EDTA Plasma

Status:

Experienced Running

Required Sample Volume:

50 µL/well

Sensitivity-LLOQ/ULOQ:

LLOQ: 46.3 pg/mL
ULOQ: 75,300 pg/mL

Biological or Clinical Significance:

IL-31 is a cytokine with a four-helix bundle structure, which is preferentially produced by type 2 helper T cells (Th2). The structure of IL-31 places it in the IL-6 family of cytokines. IL-31 signals via a receptor complex that is composed of IL-31 receptor A (IL31RA) and oncostatin M receptor subunits. These receptor subunits are expressed in activated monocytes and in unstimulated epithelial cells. IL-31 is believed to play a role in inflammation of the skin.

References:

  • Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA (July 2004). “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice”. Nat. Immunol. 5 (7): 752–60.

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies